{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "Emcyt",
      "indication": "INDICATIONS AND USAGE EMCYT Capsules are indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.",
      "manufacturer": "Pharmacia and Upjohn Company LLC",
      "splSetId": "a9b01bc6-95ac-46f9-befa-d845a74d53c1"
    }
  ],
  "id": "Estramustine_Phosphate_Sodium",
  "nciThesaurus": {
    "casRegistry": "52205-73-9",
    "chebiId": "CHEBI:31562",
    "chemicalFormula": "C23H30Cl2NO6P.2Na",
    "definition": "The orally available disodium salt, monohydrate, of estramustine phosphate, a synthetic molecule that combines estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects.",
    "fdaUniiCode": "75F375MT2N",
    "identifier": "C480",
    "preferredName": "Estramustine Phosphate Sodium",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C25974",
      "C697"
    ],
    "synonyms": [
      "ESTRAMUSTINE PHOSPHATE SODIUM",
      "Emcyt",
      "Estracyt",
      "Estramustine 17-(Dihydrogenphosphate) Disodium Salt",
      "Estramustine Phosphate",
      "Estramustine Phosphate Sodium",
      "Estramustine Sodium Phosphate",
      "Estramustine phosphate",
      "Estramustine sodium phosphate",
      "Leo 299",
      "Leo-299",
      "Ro-21-8837/001"
    ]
  }
}